Webinars

A Gut/Liver microphysiological system for profiling human oral bioavailability
Webinar Series 7 Episode 4
Explore how the innovative Gut/Liver microphysiological system (MPS) enhances in vitro ADME profiling by linking primary human intestinal and liver cells to predict human drug bioavailability more accurately. This webinar demonstrates improved predictive capacity for complex drug behaviors, advancing drug discovery and safety assessment.
Blogs

Evaluating Caco-2 cell’s gold-standard status in absorption, permeability and bioavailability Studies: Are Their Limitations Justified?
In the realm of pharmaceutical research, Caco-2 cells have long been heralded as the gold standard for studying intestinal absorption and permeability.
Blogs

6 Challenges in ADME Drug Development
Explore the current challenges in profiling preclinical human ADME through key publications. Can advances in the human relevance of preclinical models improve estimations for safer and more efficient drug development?
Scientific publications

Liver-on-chip model and application in predictive genotoxicity and mutagenicity of drugs
Kopp et al., 2024. Current pre-clinical drug safety assessments lack a single, comprehensive test system for genotoxicity hazards identification. This study, aimed to develop an in vitro model to addresses this gap, looks at Organ-on-a-chip (OOC) technology as a solution. OOC present robust human metabolic activity and has the potential to assess all required endpoints for genotoxicity hazards identification, ultimately streamlining the process and eliminating the need for animal testing. This proof-of-concept experiment demonstrates the potential of PhysioMimix® Liver-on-a-chip model as a promising tool for in vitro genotoxicity hazards identification, paving the way for a more streamlined and animal-free pre-clinical drug safety assessment process.
Posters

Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS
Improve in vitro to in vivo data translation for drug safety and efficacy with our fluidically-linked dual-organ MPS (microphysiological system); combining two well-characterized human Gut/Liver MPS – the RepliGut® Jejunum and PhysioMimix® Liver MPS, in an interconnected model suitable for enhanced bioavailability profiling.
Blogs

How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials
This blog explores a world where novel multi-organ in vitro models, tiny replicas of the human intestine and liver, provide the key to unlocking a deeper understanding of how we Absorb, Distribute and Metabolize drugs.
Read more to discover why accurately estimating human ADME remains a challenge and a potential solution that enables greater confidence in lead candidates and a reduced risk of identifying poor oral bioavailability during first in human studies.
Application notes

Connecting the gut and liver
A human-relevant dual-organ microphysiological system connecting the gut and liver for preclinical profiling of oral bioavailability
Discover a new PhysioMimix® microphysiological system (MPS) that connects primary human RepliGut® and liver models to overcome the limitations of preclinical drug ADME profiling. Download the Application Note to explore the MPS’ evaluation of Temocapril and Midazolam, demonstrating its ability to provide more accurate predictions and change the risk calculus for safer and more efficient drug development.
Posters

Connecting the human intestine and liver
A primary jejunum and primary hepatocyte multi-organ MPS for more predictive studies of human drug ADME and oral bioavailability
Traditional immortalized intestinal cell lines and suspension hepatocytes have absent or low levels of metabolic enzyme expression, and thus fail to predict first pass human metabolism and oral bioavailability.
Efforts to improve the in vitro to in vivo translation of drug efficacy and safety data has led to the emergence of more human relevant microphysiological systems (MPS) that consist of multiple, fluidically linked organs1.
Articles

Harnessing Microphysiological Systems to Bring Humanized Processes to ADME and Bioavailability Studies
Dr. Abbas discusses the common drawbacks of using conventional methods for ADME studies that can misinform the candidate selection process and dosage figures. He talks about how emerging complementary technologies, such as organ-on-a-chip (OOC), offer human-relevant in vitro preclinical data, and how using OOC can support the determination of human bioavailability to support drug dosing regiments, reduce side effects, and potentially recover flawed therapeutic candidates.
Brochures & Flyers

Organ-on-a-chip Contract Research Services Brochure
Discover our full range of Organ-on-a-chip contract research services including ADME, NASH, DILI and Oncology as well as all the relevant endpoints.
Posters

A primary jejunum and primary hepatocyte multi-organ MPS
Find out how our gut-liver MPS recapitulates the physiological condition enabling oral drug dosing in vitro. This gut-liver model offers a vast improvement in the methods used to study PK or prodrugs.
Articles

ADME Studies: Determining Promising Drug Compounds
Dr Abbas discusses factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.
This article is taken from PharmTech, November 2022.